NCT00782509 - 12 / 48 wk Pivotal PFT vs PBO in COPD II | Biotech Hunter

Enrollment

644

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

September 30, 2010

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Olodaterol (BI 1744)

Comparison of low and high doses on efficacy and safety in COPD patients

DRUG

Olodaterol (BI 1744)

Comparison of low and high doses on efficacy and safety in COPD patients

DRUG

Placebo

Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler

Trial Locations (51)

Unknown

1222.12.1227 Boehringer Ingelheim Investigational Site, Mobile

1222.12.1218 Boehringer Ingelheim Investigational Site, Wheat Ridge

1222.12.1226 Boehringer Ingelheim Investigational Site, Wheat Ridge

1222.12.1214 Boehringer Ingelheim Investigational Site, Waterbury

1222.12.1207 Boehringer Ingelheim Investigational Site, Clearwater

1222.12.1224 Boehringer Ingelheim Investigational Site, Panama City

1222.12.1222 Boehringer Ingelheim Investigational Site, Tampa

1222.12.1208 Boehringer Ingelheim Investigational Site, Winter Park

1222.12.1220 Boehringer Ingelheim Investigational Site, River Forest

1222.12.1229 Boehringer Ingelheim Investigational Site, New Orleans

1222.12.1219 Boehringer Ingelheim Investigational Site, Ann Arbor

1222.12.1209 Boehringer Ingelheim Investigational Site, Livonia

1222.12.1233 Boehringer Ingelheim Investigational Site, Henderson

1222.12.1228 Boehringer Ingelheim Investigational Site, Summit

1222.12.1206 Boehringer Ingelheim Investigational Site, Albuquerque

1222.12.1205 Boehringer Ingelheim Investigational Site, Rochester

1222.12.1213 Boehringer Ingelheim Investigational Site, Elizabeth City

1222.12.1223 Boehringer Ingelheim Investigational Site, Harrisburg

1222.12.1217 Boehringer Ingelheim Investigational Site, Raleigh

1222.12.1203 Boehringer Ingelheim Investigational Site, Cincinnatti

1222.12.1201 Boehringer Ingelheim Investigational Site, Pittsburgh

1222.12.1230 Boehringer Ingelheim Investigational Site, Easley

1222.12.1216 Boehringer Ingelheim Investigational Site, Greenville

1222.12.1221 Boehringer Ingelheim Investigational Site, Dallas

1222.12.1212 Boehringer Ingelheim Investigational Site, Danville

1222.12.1211 Boehringer Ingelheim Investigational Site, Richmond

1222.12.1225 Boehringer Ingelheim Investigational Site, Richmond

1222.12.1232 Boehringer Ingelheim Investigational Site, Morgantown

1222.12.1298 Boehringer Ingelheim Investigational Site, Beijing

1222.12.1301 Boehringer Ingelheim Investigational Site, Chongqing

1222.12.1305 Boehringer Ingelheim Investigational Site, Guangzhou

1222.12.1306 Boehringer Ingelheim Investigational Site, Haikou

1222.12.1302 Boehringer Ingelheim Investigational Site, Hangzhou

1222.12.1304 Boehringer Ingelheim Investigational Site, Nanjing

1222.12.1296 Boehringer Ingelheim Investigational Site, Shanghai

1222.12.1297 Boehringer Ingelheim Investigational Site, Shanghai

1222.12.1303 Boehringer Ingelheim Investigational Site, Wuhan

1222.12.1299 Boehringer Ingelheim Investigational Site, Xi'an

1222.12.1300 Boehringer Ingelheim Investigational Site, Xi'an

1222.12.1269 Boehringer Ingelheim Investigational Site, Berlin

1222.12.1270 Boehringer Ingelheim Investigational Site, Berlin

1222.12.1271 Boehringer Ingelheim Investigational Site, Berlin

1222.12.1268 Boehringer Ingelheim Investigational Site, Hamburg

1222.12.1266 Boehringer Ingelheim Investigational Site, Koblenz

1222.12.1272 Boehringer Ingelheim Investigational Site, Mannheim

1222.12.1267 Boehringer Ingelheim Investigational Site, Rüdersdorf

1222.12.1290 Boehringer Ingelheim Investigational Site, Kaohsiung City

1222.12.1289 Boehringer Ingelheim Investigational Site, Kaohsiung County

1222.12.1288 Boehringer Ingelheim Investigational Site, Taichung

1222.12.1287 Boehringer Ingelheim Investigational Site, Taipei

1222.12.1286 Boehringer Ingelheim Investigational Site, Taoyuan District